Go online to PeerView.com/CWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The management of hepatocellular carcinoma (HCC) is in the midst of a therapeutic paradigm shift. Partial hepatectomy, liver transplantation, ablation, radiation therapy, and embolization procedures remain important interventions for localized HCC, whereas sorafenib, a multikinase inhibitor, was the cornerstone of therapy for patients with extrahepatic disease. Recently, several single and combination agents (eg, atezolizumab with bevacizumab, cabozantinib, lenvatinib, nivolumab with and without ipilimumab, pembrolizumab, ramucirumab, regorafenib) have been approved and validated for treating patients with advanced HCC. Moreover, several emerging trials (eg, CheckMate -9DW, HIMALAYA, LEAP-002, and COSMIC-312) indicate that therapeutic advances for this malignancy are increasingly centered around exploiting the benefits of combination regimens with immunotherapy, as well as investigating innovative strategies such as adjuvant immunotherapy, tumor-treating fields, and combinations of systemic agents with locoregional therapies like TACE and TARE. This MasterClass and Tumor Board program will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each Tumor Board discussion will feature reflective case-centered discussion on the increasingly important role that hepatology professionals play for patients across the HCC continuum. This activity features an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients. Upon completion of this activity, participants should be better able to: Review the key clinical evidence on available systemic treatments, including multikinase, immune checkpoint, and anti-angiogenic inhibitors, for advanced HCC, Assess available and emerging combination strategies, such as targeted therapies with immunotherapy, dual checkpoint inhibition, and systemic agents with locoregional modalities across the disease spectrum of HCC, Develop personalized therapeutic plans in the first and subsequent lines of treatment for patients with advanced HCC, Incorporate multidisciplinary care approaches for the optimal management of patients with HCC, including those along the intermediate-to-advanced stage disease continuum.
View all episodes
